Developer docs
API playgroundTry for free, no card

Search company profiles

Epitomee Medical

Full company profile

uuid0002ffz

Namestring
Epitomee Medical
Legal namestring
Epitomee Medical Ltd.
Company typeenum
Public
Founded yearint
2005
Descriptiontext

Epitomee Medical Ltd. is an Israel-based, publicly traded medical device company (TASE: EPIT; founded 2005; headquartered in Caesarea) that develops ingestible therapeutic devices built on a proprietary pH-triggered, shape-shifting hydrogel scaffold platform. Its lead commercial product, the Epitomee® Capsule, is a drug-free, self-administered swallowable capsule that unfolds into a semi-rigid triangular structure in the stomach, where it applies mechanosensory stimulation to induce satiety and earlier meal termination. The capsule received CE Mark in September 2020 and FDA 510(k) clearance in September 2024 for weight management in adults with BMI 25–40 kg/m², supported by the RESET pivotal trial (n=279 across 9 US sites, 55.5% of treated patients achieving ≥5% weight loss at 24 weeks, p<0.0001 vs. 35% threshold) and eight peer-reviewed publications covering the RESET and ELECT studies. The product is positioned as a non-systemic alternative to GLP-1 agonists and bariatric procedures, and as a complement to diet and exercise for the overweight segment previously excluded from anti-obesity medications.

The company operates a secondary platform — a Biologics Delivery Platform that uses a mucoadhesive matrix patch to orally deliver biologic APIs (antibodies, peptides, hormones, proteins) to the intestinal wall, intended for licensing to pharmaceutical and biotech partners. Epitomee monetizes the weight management capsule through prescription-driven distribution: a former exclusive global license to Nestlé Health Science was cancelled in late 2023, after which the company rebuilt distribution via an exclusive Israeli agreement with Rafa (August 2025; first shipment December 2025), a German regional distributor (updated December 2025; first European order March 2026), US online pharmacy partnerships (February 2026), and an integrated-care partnership with ReviveHealth (April 2026) targeting employer-sponsored health programs. Manufacturing is conducted in-house at a dedicated production facility in Israel. The company has no disclosed revenue and operates with 11–50 employees, having raised approximately $58M cumulatively through a $51M IPO on TASE in December 2021 and prior rounds.

Short descriptiontext

Epitomee Medical is an Israel-based medical device company that develops a drug-free, FDA-cleared ingestible hydrogel capsule (Epitomee® Capsule) that expands in the stomach to induce satiety for weight management in adults with BMI 25–40, distributed through regional partners (Rafa, US online pharmacies, German distributor) and integrated care platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCaesarea, Israel
HQ citystring
Caesarea
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ingestible medical devices, weight management capsule, oral biologics delivery, hydrogel scaffold platform, obesity treatment devices
Industry2 codes
PRIMARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
SECONDARYAFAJAKAL
Delivery Systems & Encapsulation (Microencapsulation, Liposomes, Emulsions, Beadlets, Spray-Dried)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
NAICS code2 codes
  • Medical Equipment and Supplies Manufacturing3391
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Ingestible Medical Devices for Weight Management
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Product Sales — Weight Management Capsule
TypeHardware Sales
Description

Revenue from direct sales and distribution of the Epitomee Capsule for weight management. The product is sold by prescription through healthcare professionals, distributed via online pharmacies in the US, through Rafa in Israel, and through other regional distributors. Nestlé Health Science previously held global commercialization rights before the relationship was restructured.

epitomeemedical.com
2Licensing and Distribution Agreements
TypeLicensing Royalties
Description

The company generates revenue through licensing arrangements with distribution partners. The original Nestlé agreement was a strategic licensing and commercialization partnership. After Nestlé cancelled its license agreement in late 2023, the company established new distribution agreements with Rafa (exclusive Israel), US online pharmacies, and a German distributor.

epitomeemedical.com
3Platform Technology Licensing — Biologics Delivery
TypeLicensing Royalties
Description

Epitomee is seeking partnerships to enable its oral delivery platform to carry third-party APIs (active pharmaceutical ingredients) for optimized biologics administration. Revenue would come from licensing the delivery platform to pharma/biotech companies.

epitomeemedical.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Epitomee® Capsule
Description

FDA cleared and CE approved ingestible weight management capsule for adults with BMI 25-40 kg/m²

epitomeemedical.com
Core offering1 text field

Epitomee Medical develops, manufactures, and commercializes the Epitomee® Capsule, an FDA-cleared and CE-marked drug-free, self-administered ingestible shapeshifting hydrogel capsule for weight management in adults with BMI 25-40. The company also operates a broader ingestible therapeutic device platform for oral delivery of biologic drugs, partnering with pharmaceutical and biotech companies to deliver APIs via mucoadhesive patches that deploy against the intestinal wall.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 55.5% of Epitomee-treated patients achieved ≥5% body weight loss at 24 weeks (P<0.0001 vs. 35% threshold)
+7 more records
Product overview1 text field

Epitomee Medical is a medical device company offering ingestible therapeutic platforms. The portfolio consists of two core offerings: (1) the Epitomee® Capsule, an FDA-cleared and CE-marked weight management device that uses a shapeshifting hydrogel scaffold to induce satiety; and (2) a Biologics Delivery Platform designed for oral administration of biologic drugs via mucoadhesive patches that attach to the intestinal wall, offering a needle-free alternative to injections.

Product and service2 records
1Epitomee® Capsule
CategoryIngestible Weight Management Medical Device
Description

FDA-cleared and CE-marked ingestible medical device for weight management in adults with BMI 25-40 kg/m². A drug-free, self-administered shapeshifting capsule that expands in the stomach into a semi-rigid triangular configuration to create a sensation of fullness, inducing satiety and reducing caloric intake via twice-daily dosing before meals. Available by prescription through healthcare providers, regional distributors, and online pharmacies.

2Biologics Delivery Platform
CategoryOral Biologics Delivery Platform
Description

Oral delivery platform for biologic drugs using shape-shifting hydrogel scaffold technology. The platform enables targeted, protected delivery of biologic payloads (antibodies, peptides, hormones, proteins, small molecules, micronutrients) to the intestinal wall via a mucoadhesive matrix patch, offering a needle-free oral alternative to subcutaneous and IV injections. The company is seeking licensing partnerships with pharmaceutical and biotech companies.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierStrategic — Integrated Care ModelTypeStrategic or Co-development PartnerAnnounced on2026-04-09
Description

ReviveHealth, a provider of integrated whole-person healthcare solutions, partnered with Epitomee to introduce the Epitomee Capsule as a non-pharmacological pathway within Revive's Weight Health program. The program targets employer-sponsored insurance members with a coaching-led, wraparound care model. The capsule is offered as a clinically guided option without stimulants, hormones, or surgical procedures.

Strategic tierCore — Exclusive Israel DistributionTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-06
Description

Rafa signed an exclusive distribution agreement (August 2025) for the marketing, distribution, and sale of Epitomee's weight loss capsule in Israel. First shipment to Rafa was delivered December 2025. Rafa is a significant Israeli pharmaceutical/healthcare distributor.

Strategic tierFormer Flagship — RestructuredTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2020-08-11
Description

Nestlé Health Science and Epitomee entered into a strategic agreement (August 2020) to develop and commercialize the Epitomee weight loss and metabolic health product globally. Nestlé received exclusive global commercialization rights. Nestlé converted $7M as part of the IPO (December 2021). Nestlé cancelled the license agreement in late 2023 after RESET trial results reportedly did not fully meet contractual thresholds. An Israeli regulatory inquiry followed (Neto authorization opened August 2025). The company subsequently established alternative distribution channels including Rafa (Israel), US online pharmacies, and German distributor. The company presentation (May 2026) indicates Nestlé remains a key partner reference.

Strategic tierMinor — Operational SupportTypeOthers
Description

PearlCom provides Strategy, UI & UX services for the Epitomee website and digital presence.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in obesity pharmacotherapy with Wegovy and Saxenda (GLP-1 agonists). Represents the dominant incumbent alternative to Epitomee's drug-free approach and the principal competitive pressure shaping prescriber and payer behavior in the weight-loss category.

TypeDirect peer
Description

Pioneered a swallowable, gas-filled intragastric balloon system for weight loss. Although the company wound down operations, it remains a historically relevant peer demonstrating the challenges and competitive dynamics of swallowable weight-management devices.

TypeBroad incumbent
Description

Markets Mounjaro/Zepbound (tirzepatide) for obesity, currently the most effective approved pharmacotherapy. A broad incumbent whose commercial reach and clinical evidence base materially influence the strategic positioning of all non-GLP-1 weight-loss devices.

TypeEmerging player
Description

Developer of the Spatz3 adjustable intragastric balloon for non-surgical weight loss. Operates in the same clinical weight-management device category as Epitomee, though using a balloon (endoscopically placed and adjustable) rather than an ingestible capsule.

TypeEmerging player
Description

Sells the ReShape Vest system and previously marketed the ReShape Intragastric Balloon for weight loss. Operates in the medical-device weight-loss category with overlapping customer segments (clinicians, integrated care providers).

TypeDirect peer
Description

Developed Plenity, an oral superabsorbent hydrogel capsule for weight management that expands in the stomach to induce satiety — the closest mechanistic and clinical analog to Epitomee's ingestible hydrogel capsule. Both target adults with overweight/obesity via a drug-free, mechanical mechanism and have pursued FDA clearance.

TypeBroad incumbent
Description

Diversified global medical-device incumbent with adjacent obesity/metabolic health and GI device portfolios. Represents the type of strategic acquirer or large partner that could commercialize Epitomee's technology at scale.

TypeDirect peer
Description

Maker of the Elipse swallowable gastric balloon for weight loss — a procedurally similar ingestible, self-administered weight-management device (though balloon-based rather than hydrogel-based). Targets a similar patient population through a comparable non-surgical, outpatient model.

TypeDirect peer
Description

Develops the RaniPill, an ingestible capsule designed to deliver biologics (including peptides and antibodies) orally by injecting them into the intestinal wall. Directly comparable to Epitomee's Biologics Delivery Platform, which uses mucoadhesive matrix patches for the same therapeutic intent.

TypeEmerging player
Description

Develops long-acting oral drug delivery platforms, including ingestible capsules that slowly release drug payloads in the GI tract over days to weeks. Adjacent to Epitomee's oral biologics delivery efforts and a potential partner or competitor in oral sustained-release delivery.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Epitomee Medical

Ingestible Medical Devices for Weight Managementepitomeemedical.com

Epitomee Medical is an Israel-based medical device company that develops a drug-free, FDA-cleared ingestible hydrogel capsule (Epitomee® Capsule) that expands in the stomach to induce satiety for weight management in adults with BMI 25–40, distributed through regional partners (Rafa, US online pharmacies, German distributor) and integrated care platforms.

What Epitomee Medical does

Epitomee Medical Ltd. is an Israel-based, publicly traded medical device company (TASE: EPIT; founded 2005; headquartered in Caesarea) that develops ingestible therapeutic devices built on a proprietary pH-triggered, shape-shifting hydrogel scaffold platform. Its lead commercial product, the Epitomee® Capsule, is a drug-free, self-administered swallowable capsule that unfolds into a semi-rigid triangular structure in the stomach, where it applies mechanosensory stimulation to induce satiety and earlier meal termination. The capsule received CE Mark in September 2020 and FDA 510(k) clearance in September 2024 for weight management in adults with BMI 25–40 kg/m², supported by the RESET pivotal trial (n=279 across 9 US sites, 55.5% of treated patients achieving ≥5% weight loss at 24 weeks, p<0.0001 vs. 35% threshold) and eight peer-reviewed publications covering the RESET and ELECT studies. The product is positioned as a non-systemic alternative to GLP-1 agonists and bariatric procedures, and as a complement to diet and exercise for the overweight segment previously excluded from anti-obesity medications.

The company operates a secondary platform — a Biologics Delivery Platform that uses a mucoadhesive matrix patch to orally deliver biologic APIs (antibodies, peptides, hormones, proteins) to the intestinal wall, intended for licensing to pharmaceutical and biotech partners. Epitomee monetizes the weight management capsule through prescription-driven distribution: a former exclusive global license to Nestlé Health Science was cancelled in late 2023, after which the company rebuilt distribution via an exclusive Israeli agreement with Rafa (August 2025; first shipment December 2025), a German regional distributor (updated December 2025; first European order March 2026), US online pharmacy partnerships (February 2026), and an integrated-care partnership with ReviveHealth (April 2026) targeting employer-sponsored health programs. Manufacturing is conducted in-house at a dedicated production facility in Israel. The company has no disclosed revenue and operates with 11–50 employees, having raised approximately $58M cumulatively through a $51M IPO on TASE in December 2021 and prior rounds.

Epitomee Medical firmographics

Firmographics
Name
Epitomee Medical
Legal name
Epitomee Medical Ltd.
Website
https://epitomeemedical.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
Epitomee Medical is an Israel-based medical device company that develops a drug-free, FDA-cleared ingestible hydrogel capsule (Epitomee® Capsule) that expands in the stomach to induce satiety for weight management in adults with BMI 25–40, distributed through regional partners (Rafa, US online pharmacies, German distributor) and integrated care platforms.
Ownership category
akta.pro rank

Epitomee Medical industry classification

Industry
Product category
Ingestible Medical Devices for Weight Management
NAICS
Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
SECONDARYAFAJAKAL
Delivery Systems & Encapsulation (Microencapsulation, Liposomes, Emulsions, Beadlets, Spray-Dried)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)

Keywords

  • Ingestible medical devices
  • Weight management capsule
  • Oral biologics delivery
  • Hydrogel scaffold platform
  • Obesity treatment devices

Where Epitomee Medical is headquartered

Location

Headquarters

HQ city
Caesarea
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Epitomee Medical business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

  1. Product Sales — Weight Management Capsule: Revenue from direct sales and distribution of the Epitomee Capsule for weight management. The product is sold by prescription through healthcare professionals, distributed via online pharmacies in the US, through Rafa in Israel, and through other regional distributors. Nestlé Health Science previously held global commercialization rights before the relationship was restructured.
  2. Licensing and Distribution Agreements: The company generates revenue through licensing arrangements with distribution partners. The original Nestlé agreement was a strategic licensing and commercialization partnership. After Nestlé cancelled its license agreement in late 2023, the company established new distribution agreements with Rafa (exclusive Israel), US online pharmacies, and a German distributor.
  3. Platform Technology Licensing — Biologics Delivery: Epitomee is seeking partnerships to enable its oral delivery platform to carry third-party APIs (active pharmaceutical ingredients) for optimized biologics administration. Revenue would come from licensing the delivery platform to pharma/biotech companies.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

Epitomee Medical product offering

Product offering

Core offering

Epitomee Medical develops, manufactures, and commercializes the Epitomee® Capsule, an FDA-cleared and CE-marked drug-free, self-administered ingestible shapeshifting hydrogel capsule for weight management in adults with BMI 25-40. The company also operates a broader ingestible therapeutic device platform for oral delivery of biologic drugs, partnering with pharmaceutical and biotech companies to deliver APIs via mucoadhesive patches that deploy against the intestinal wall.

Product overview

Epitomee Medical is a medical device company offering ingestible therapeutic platforms. The portfolio consists of two core offerings: (1) the Epitomee® Capsule, an FDA-cleared and CE-marked weight management device that uses a shapeshifting hydrogel scaffold to induce satiety; and (2) a Biologics Delivery Platform designed for oral administration of biologic drugs via mucoadhesive patches that attach to the intestinal wall, offering a needle-free alternative to injections.

Differentiator

Problem solved

Functional benefit

Brands

  • Epitomee® Capsule: FDA cleared and CE approved ingestible weight management capsule for adults with BMI 25-40 kg/m²

Products and services

  • Epitomee® Capsule FDA-cleared and CE-marked ingestible medical device for weight management in adults with BMI 25-40 kg/m². A drug-free, self-administered shapeshifting capsule that expands in the stomach into a semi-rigid triangular configuration to create a sensation of fullness, inducing satiety and reducing caloric intake via twice-daily dosing before meals. Available by prescription through healthcare providers, regional distributors, and online pharmacies.
  • Biologics Delivery Platform Oral delivery platform for biologic drugs using shape-shifting hydrogel scaffold technology. The platform enables targeted, protected delivery of biologic payloads (antibodies, peptides, hormones, proteins, small molecules, micronutrients) to the intestinal wall via a mucoadhesive matrix patch, offering a needle-free oral alternative to subcutaneous and IV injections. The company is seeking licensing partnerships with pharmaceutical and biotech companies.

Quantifiable outcome

  • 55.5% of Epitomee-treated patients achieved ≥5% body weight loss at 24 weeks (P<0.0001 vs. 35% threshold)
  • +7 more outcomes

Companies that use Epitomee Medical

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Epitomee Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Epitomee Medical partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered strategic — integrated care model, core — exclusive israel distribution, former flagship — restructured and minor — operational support.

  • ReviveHealthstrategic — integrated care modelStrategic or Co-development Partner · 9 April 2026ReviveHealth, a provider of integrated whole-person healthcare solutions, partnered with Epitomee to introduce the Epitomee Capsule as a non-pharmacological pathway within Revive's Weight Health program. The program targets employer-sponsored insurance members with a coaching-led, wraparound care model. The capsule is offered as a clinically guided option without stimulants, hormones, or surgical procedures.
  • Rafa (רפא)core — exclusive israel distributionChannel Partner/ Reseller/ Distributor · 6 August 2025Rafa signed an exclusive distribution agreement (August 2025) for the marketing, distribution, and sale of Epitomee's weight loss capsule in Israel. First shipment to Rafa was delivered December 2025. Rafa is a significant Israeli pharmaceutical/healthcare distributor.
  • Nestlé Health Scienceformer flagship — restructuredOEM/ Whitelabel/ Licensing Partner · 11 August 2020Nestlé Health Science and Epitomee entered into a strategic agreement (August 2020) to develop and commercialize the Epitomee weight loss and metabolic health product globally. Nestlé received exclusive global commercialization rights. Nestlé converted $7M as part of the IPO (December 2021). Nestlé cancelled the license agreement in late 2023 after RESET trial results reportedly did not fully meet contractual thresholds. An Israeli regulatory inquiry followed (Neto authorization opened August 2025). The company subsequently established alternative distribution channels including Rafa (Israel), US online pharmacies, and German distributor. The company presentation (May 2026) indicates Nestlé remains a key partner reference.
  • PearlComminor — operational supportOthersPearlCom provides Strategy, UI & UX services for the Epitomee website and digital presence.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Epitomee Medical competitors and assessment

Company assessment

Broad incumbents

  • Novo Nordisk: Global leader in obesity pharmacotherapy with Wegovy and Saxenda (GLP-1 agonists). Represents the dominant incumbent alternative to Epitomee's drug-free approach and the principal competitive pressure shaping prescriber and payer behavior in the weight-loss category.
  • Eli Lilly: Markets Mounjaro/Zepbound (tirzepatide) for obesity, currently the most effective approved pharmacotherapy. A broad incumbent whose commercial reach and clinical evidence base materially influence the strategic positioning of all non-GLP-1 weight-loss devices.
  • Boston Scientific: Diversified global medical-device incumbent with adjacent obesity/metabolic health and GI device portfolios. Represents the type of strategic acquirer or large partner that could commercialize Epitomee's technology at scale.

Direct peers

  • Obalon Therapeutics: Pioneered a swallowable, gas-filled intragastric balloon system for weight loss. Although the company wound down operations, it remains a historically relevant peer demonstrating the challenges and competitive dynamics of swallowable weight-management devices.
  • Gelesis: Developed Plenity, an oral superabsorbent hydrogel capsule for weight management that expands in the stomach to induce satiety — the closest mechanistic and clinical analog to Epitomee's ingestible hydrogel capsule. Both target adults with overweight/obesity via a drug-free, mechanical mechanism and have pursued FDA clearance.
  • Allurion Technologies: Maker of the Elipse swallowable gastric balloon for weight loss — a procedurally similar ingestible, self-administered weight-management device (though balloon-based rather than hydrogel-based). Targets a similar patient population through a comparable non-surgical, outpatient model.
  • Rani Therapeutics: Develops the RaniPill, an ingestible capsule designed to deliver biologics (including peptides and antibodies) orally by injecting them into the intestinal wall. Directly comparable to Epitomee's Biologics Delivery Platform, which uses mucoadhesive matrix patches for the same therapeutic intent.

Emerging players

  • Spatz Medical: Developer of the Spatz3 adjustable intragastric balloon for non-surgical weight loss. Operates in the same clinical weight-management device category as Epitomee, though using a balloon (endoscopically placed and adjustable) rather than an ingestible capsule.
  • ReShape Lifesciences: Sells the ReShape Vest system and previously marketed the ReShape Intragastric Balloon for weight loss. Operates in the medical-device weight-loss category with overlapping customer segments (clinicians, integrated care providers).
  • Lyndra Therapeutics: Develops long-acting oral drug delivery platforms, including ingestible capsules that slowly release drug payloads in the GI tract over days to weeks. Adjacent to Epitomee's oral biologics delivery efforts and a potential partner or competitor in oral sustained-release delivery.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Epitomee Medical compliance and trust

Trust signal

Compliance2 records

Epitomee Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Epitomee Medical leadership team

Management profile

Number of profiles

Profiles16 records

Epitomee Medical funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Epitomee Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Epitomee Medical

What does Epitomee Medical do?

Epitomee Medical develops, manufactures, and commercializes the Epitomee® Capsule, an FDA-cleared and CE-marked drug-free, self-administered ingestible shapeshifting hydrogel capsule for weight management in adults with BMI 25-40. The company also operates a broader ingestible therapeutic device platform for oral delivery of biologic drugs, partnering with pharmaceutical and biotech companies to deliver APIs via mucoadhesive patches that deploy against the intestinal wall.

Is Epitomee Medical a public or private company?

Epitomee Medical is a public company. It is classified as public and is currently operating.

When was Epitomee Medical founded?

Epitomee Medical was founded in 2005. It employs 11 to 50 people.

Where is Epitomee Medical based?

Epitomee Medical is headquartered in Caesarea, Israel, in the Middle East region.

How does Epitomee Medical make money?

Three revenue lines are on record. Product Sales — Weight Management Capsule is the primary driver. The others are licensing and Distribution Agreements and platform Technology Licensing — Biologics Delivery.

Who are Epitomee Medical's main competitors?

Broad incumbents on record are Novo Nordisk, Eli Lilly and Boston Scientific. Direct peers are Obalon Therapeutics, Gelesis, Allurion Technologies and Rani Therapeutics. Emerging players are Spatz Medical, ReShape Lifesciences and Lyndra Therapeutics.

Does Epitomee Medical have an API?

No public API is recorded for Epitomee Medical.

What industry is Epitomee Medical in?

Epitomee Medical's product category is Ingestible Medical Devices for Weight Management. Its primary akta.pro industry code is HLAAAFAJ, Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery), with a secondary code of AFAJAKAL, Delivery Systems & Encapsulation (Microencapsulation, Liposomes, Emulsions, Beadlets, Spray-Dried). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Jerusalem PostCompany that concealed information from investors slapped with fineThe Israeli Securities Authority fined Epitomee Medical, its former CEO, and chairman NIS 1.85 million for misleading investor reports. The company concealed data showing it failed to meet Nestle's efficacy targets, threatening the distribution agreement. The ruling cited negligence in disclosing material information.Simply Wall StMiddle Eastern Penny Stocks With Market Caps Under US$100MAmid rising US-Iran tensions causing losses across most Gulf stock markets, this article examines three Middle Eastern penny stocks that may offer value appreciation potential. The profiled companies include Turkish packaging firm Duran Dogan Basim ve Ambalaj Sanayi A.S. (market cap TRY2.5B, unprofitable but improving), Turkish IT/healthcare provider Fonet Bilgi Teknolojileri A.S. (market cap TRY4.51B, with 70% earnings growth), and Israeli medical device company Epitomee Medical Ltd (market cap ₪104.45M, pre-revenue but debt-free). The article notes these stocks carry typical penny stock volatility despite the financial metrics highlighted.EIN PresswireReviveHealth Expands Weight Health Program with Additional Care Pathways to Support Long-Term Health OutcomesReviveHealth expanded its Weight Health program with a non-pharmacological option from Epitomee Medical, introducing the Epitomee Capsule for weight management. The capsule is a prescription-only, non-drug tool that helps patients feel full sooner without stimulants, hormones, or surgery. It is integrated into Revive's coaching-led care model, offering an alternative for those who cannot tolerate GLP-1 medications.GlobesEpitomee Medical's slimming pill approved in EuropeEpitomee Medical received EU approval for its weight-loss capsule, removing the final barrier to European marketing. A German distributor committed to ordering $5.3 million over 12 months, with $110,000 for immediate delivery. The company expects to fill the immediate order soon, subject to security in Israel.PR NewswireEpitomee and Nestlé Health Science Announced Completion of Patient Enrollment in Epitomee's Weight Loss Capsule Pivotal Study (United States)Epitomee and Nestlé Health Science announced completion of patient enrollment for the Epitomee weight loss capsule pivotal study, conducted at leading medical centers across the United States. The randomized, controlled, multi-center study has two co-primary endpoints: demonstrating superiority versus the control arm and showing that at least 5% of patients lost 5% or more of their baseline body weight over 24 weeks of treatment. Study completion and results are expected in the second half of 2023, after which Epitomee will apply for FDA approval, with Nestlé Health Science holding exclusive global commercialization rights.PR NewswireEpitomee Medical announced the completion of $51 million IPO on the Tel Aviv Stock Exchange; The offering was made at a pre-money valuation of $200 millionEpitomee Medical, an Israel-based biomedical company, completed a $51 million IPO on the Tel Aviv Stock Exchange at a pre-money valuation of $200 million on a fully diluted basis. The offering was led by Leumi Partners and Barak Capital with participation from institutional investors including leading insurance companies, and the stock will begin trading under the symbol EPIT. Proceeds will be used to establish production lines, obtain FDA approval for the Epitomee Capsule weight management solution, and further develop the company's pipeline of ingestible therapeutic medical devices.IFTTTShimon Eckhouse brings Epitomee Medical to TASEEpitomee Medical, founded by Shimon Eckhouse, floated on TASE, raising NIS 162 million at a NIS 632 million valuation. Nestlé converted a $7 million loan to equity, bringing total proceeds to NIS 187 million. The company plans commercial production in early 2023.PR NewswireEpitomee Medical Ltd. and Nestlé Health Science Announced Partnership for Development and Commercialization of the Epitomee Weight Loss CapsuleEpitomee Medical, a privately held Israeli biomedical company, announced a strategic partnership with Nestlé Health Science granting the latter exclusive global commercial rights to Epitomee's weight loss capsule product. The Epitomee Capsule is a patented medical device that has demonstrated safety and efficacy in preclinical and clinical studies, with significant weight reduction results, and will be sold under prescription in the US and Europe. The deal, described as transformational by Epitomee's CEO, enables worldwide scale-up through Nestlé Health Science's global marketing and sales channels to address the approximately 1 billion people globally affected by overweight and metabolic disorders.FinSMEsEpitomee Closed $8M Equity Financing RoundEpitomee Medical, an Israeli bio-medical company, closed an $8M equity financing round led by XT Hi-Tech. The funds will advance its Epitomee Capsule, a swallowable device for weight loss and glycemic control, with a Phase 2B study planned over 24 weeks.